February 21-23, 2012 | San Francisco, CA | Part of the 19th International Molecular Med Tri-Conference - www.triconference.com
Translational sciences can help increase not only the speed at which a drug reaches the clinic, but also the efficacy of the drug, the safety profile of that drug and the treatment population. Cambridge Healthtech Institute's Eighth Annual Translational Science conference at the 2012 Molecular Med Tri-Con will bring scientists from academia, industry and government together to discuss the role of translational science in drug discovery and development. While remaining in the forefront of pharmaceutical development news, translational science has become an integral component of modern drug discovery, starting with target validation and continuing through post-market surveillance. The role of the translational scientist may vary from organization to organization, but the underlying need to better understand and utilize the knowledge from both clinical and pre-clinical endeavors is crucial to reducing pharmaceutical attrition. What is the impact of having a pharmacodynamic vs. a prognostic biomarker? Can you implement a translational approach in a drug-diagnostic co-development project? What is the modern role for in vivo models in translational science? Learn from the experts and contribute to the conversation by bringing your experience to the forefront through interactive roundtables, moderated panel discussions and networking breaks. Case studies (from both small molecule and biologics) will be presented with an emphasis on the role of translational science in the success or failure of the compound. What are the lessons learned from the successes? Learn how these results are already translating back to pre-clinical research for similar targets.
KEYNOTE PRESENTATIONS:
Use of Biomarkers and Translational Science to Improve and Accelerate Oncology Drug Development
J. Carl Barrett, Ph.D., Vice President, Translational Medicine, AstraZeneca
Cancer Pharmacology in Translational Medicine
Z. Alex Cao, Ph.D., Associate Director, Oncology Translational Research, Novartis Oncology Translational Medicine
Presentations Include:
Impact and Translational Opportunities of Pre-Clinical Imaging in Biomarker Discovery and Drug Development
Paul McCracken, Ph.D., Director, Imaging, Eisai Research Institute
Integrating Imaging in Early Drug Development:
Glenn Liu, M.D., Associate Professor, Medicine, Carbone Cancer Center, Wisconsin Institute for Medical Research, University of Wisconsin
Translational Imaging for De-risking Pharmaceutical Pipelines
Yanping Luo, Ph.D., Group Leader, Translational Imaging, Global Pharmaceutical R&D, Abbott Laboratories
SOMAmers Enable High Throughput Screening for Protein Biomarkers and Diagnostics
Stephen A Williams, M.D., Ph.D., CMO, SomaLogic
Use and Validation of Image Based Biomarkers of Drug Response: a CRO Perspective
Patrick McConville, Ph.D., Chief Scientific Officer/COO, Molecular Imaging, Inc.
PET Imaging as a Quantitative Biomarker in CNS Drug Development:
Yiyun Henry Huang, Ph.D., Associate Professor, Co-Director, PET Center, Department of Diagnostic Radiology, Yale University
The JAX Cancer Consortium: Changing the Course of Clinical Advancement
Brandy Wilkinson, Ph.D., In Vivo Study Director, The Jackson Laboratory-West
PANEL DISCUSSION: How Have Biomakers Been Applied in Clinical Development?
Moderator: Prakash Purohit, Ph.D., Associate Director, Scientific Affairs, IPSEN Biomeasure, Inc.
From Bench to Clinic: Quantitatively Assessing Cancer Targets and Biomarkers for Targeted Therapies
Corinne Ramos, Ph.D., Executive Director of Clinical Research, Theranostics Health
Biomarkers: How to Find them and Apply Them in Clinical Trials
Suso Platero, Ph.D., Director, Oncology Biomarkers, Centocor, Ortho Biotech Oncology Research & Development, a unit of J&J PRD, LLC
Back to Biomarker Basics for Drug Development
Terry Walker, Ph.D., Director, Translational Immunology, Immunology & Autoimmunity Research Unit, Pfizer
Molecular Profiling of Breast Cancer Trial Sets to Unravel Driving Oncogenic Hubs and Parallel Pathways
Brian Leyland-Jones, M.D., Ph.D., Director, Winship Cancer Institute, Emory University
Use of Experimental Medicine Models for Detecting Target Engagement in Clinical Trials of TRPV1 Antagonists
Samer Eid, Ph.D.,Team Leader, Pain & Migraine Research, Neuroscience Drug Discovery, Merck Research Laboratories
Biomarker Discovery and Validation: What is Missing
Joerg Heyer, Ph.D., Director, Genetic Models, Translational Research, AVEO Pharmaceuticals
Translational Research at Scripps Florida
Patrick Griffin, Ph.D., Director, Translational Research, The Scripps Research Institute
Translating Innovation into Personalized Medicine: A Centralized Approach for Fostering Research and Engaging Physicians in a Large National Community Hospital Network
Jeffrey M. Otto, Ph.D., M.B.A., National Director, Catholic Health Initiative's Center for Translational Research
Driving Innovation with Forward and Reverse Translation in the Academic Setting
Bruce A. Sullenger, Ph.D., Director of the Duke Center for Translational Research, Joseph and Dorothy Beard Professor, Department of Surgery, Duke University Medical Center
T-Cell Immunotherapy at UPenn: An Integrated Academic Translational Model for Success
Michael Kalos, Ph.D., Director, Translational and Correlative Studies Laboratory, University of Pennsylvania School of Medicine
Collaboration in Translational Science: Leveraging the Best of Both Worlds
Moderator: Patricia McDonald, Ph.D., Associate Scientific Director, Translational Research, The Scripps Research Institute
Informatics Tools for Translational Science: Bench to Bedside and Back
James Cai, Ph.D., Head, Disease & Translational Informatics, Pharma Research & Early Development (pRED) Informatics, F. Hoffmann-La Roche, Inc.
Building a Translational Informatics Infrastructure Organically
Shoibal Datta, Ph.D., Associate Director, R&D Information Technology, Therapeutic Areas & Translational Medicine, Biogen Idec, Inc
Implementation of Translational Research Informatics Platform at City of Hope
Ajay Shah, Ph.D., Director, Research Informatics, City of Hope
For more information visit http://www.triconference.com/
# # #
Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.
